Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVBGet Free Report) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Price Performance

Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.17. The business’s fifty day moving average price is $0.03 and its 200 day moving average price is $0.05.

Navidea Biopharmaceuticals Company Profile

(Get Free Report)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

See Also

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.